The estimated Net Worth of J Martin Carroll is at least $429 Tysiąc dollars as of 10 May 2023. Mr. Carroll owns over 31,500 units of Mallinckrodt Plc stock worth over $12,410 and over the last 12 years he sold MNK stock worth over $0. In addition, he makes $416,896 as Independent Director at Mallinckrodt Plc.
Sign up
Mr. Carroll MNK stock SEC Form 4 insiders trading
J has made over 9 trades of the Mallinckrodt Plc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 31,500 units of MNK stock worth $48,825 on 10 May 2023.
The largest trade he's ever made was exercising 96,864 units of Mallinckrodt Plc stock on 10 August 2021 worth over $32,934. On average, J trades about 2,780 units every 56 days since 2013. As of 10 May 2023 he still owns at least 36,500 units of Mallinckrodt Plc stock.
You can see the complete history of Mr. Carroll stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
J. Martin Carroll biography
J. Martin Carroll is Independent Director of Mallinckrodt Public Limited Company. He served as President and Chief Executive Officer of Boehringer Ingelheim Corporation and of Boehringer Pharmaceuticals, Inc. from 2003 until 2011 and as a director of Boehringer Ingelheim Corporation from 2003 until December 2012. He joined the organization in 2002 as President of Boehringer Pharmaceuticals, Inc. Mr. Carroll worked at Merck & Company, Inc. from 1976 to 2001. From 1972 to 1976, Mr. Carroll served in the United States Air Force where he attained the rank of Captain. He has served as a director of Therapeutics MD, Inc. since March 2015, as a director of Catalent Pharma Solutions since July 2015 and served as a director of Inotek from March 2016 and as Chairman of Inotek from June 2016 until January 2018. Mr. Carroll served as a director of Durata Therapeutics, Inc. from August 2014 until November 2014 when it was acquired by Actavis and as a director of Vivus, Inc. from May 2013 until September 2014. Mr. Carroll’s qualifications to serve on our Board include his significant experience in leadership positions at pharmaceutical companies.
What is the salary of J Carroll?
As the Independent Director of Mallinckrodt Plc, the total compensation of J Carroll at Mallinckrodt Plc is $416,896. There are 8 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
How old is J Carroll?
J Carroll is 70, he's been the Independent Director of Mallinckrodt Plc since 2013. There are no older and 13 younger executives at Mallinckrodt Plc.
What's J Carroll's mailing address?
J's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48187.
Insiders trading at Mallinckrodt Plc
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... oraz Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
What does Mallinckrodt Plc do?
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
What does Mallinckrodt Plc's logo look like?
Complete history of Mr. Carroll stock trades at Esperion Therapeutics, VIVUS, Catalent, Mallinckrodt Plc, TherapeuticsMD oraz TherapeuticsMD Inc
Mallinckrodt Plc executives and stock owners
Mallinckrodt Plc executives and other stock owners filed with the SEC include:
-
Mark Trudeau,
President, Chief Executive Officer, Director -
Steven Romano,
Executive Vice President, Chief Scientific Officer -
Hugh O'Neill,
Executive Vice President, Chief Commercial Officer -
Mark Casey,
Executive Vice President and Chief Legal Officer -
Bryan Reasons,
Chief Financial Officer, Executive Vice President -
Ian Watkins,
Chief Human Resource Officer, Executive Vice President -
Angus Russell,
Independent Non-Executive Chairman of the Board -
JoAnn Reed,
Independent Director -
J. Martin Carroll,
Independent Director -
David Norton,
Independent Director -
Kneeland Youngblood,
Independent Director -
Anne Whitaker,
Independent Director -
Paul Carter,
Independent Director -
Carlos Paya,
Independent Director -
Daniel Speciale,
Vice President - Investor Relations and IRO -
David R Carlucci,
Director -
Virgil D Thompson,
Director -
Diane H. Gulyas,
Director -
Matthew K Harbaugh,
SVP&Chief Financial Officer -
Michael Bryant Hicks,
Sr. VP & General Counsel -
Ronald K. Lloyd,
Sr. VP & Pres, Hospital -
Raymond J. Furey,
SVP & Chief Compliance Officer -
Gary M. Phillips,
Sr. VP & Chief Strategy Ofcr. -
Meredith B Fischer,
SVP, Communic. & Public Affair -
Melvin D Booth,
Director -
Joseph A Zaccagnino,
Director -
Coleman N Iii Lannum,
VP, Investor Relations -
Dagmar Rosa Bjorkeson,
Chief Strat & Corp Dev Officer -
Sigurdur O Olafsson,
President and CEO -
Kassie Harrold,
Chief Compliance Officer -
Jason Daniel Goodson,
EVP & Head of Corp Development -
Henriette Nielsen,
EVP & Chief Transformation OFC -
Lisa French,
EVP & Chief Commercial Officer -
Mark Anthony Tyndall,
EVP & Chief Legal Offi & Secre -
Stephen Andrew Welch,
EVP & Head of Spec Generics -
Frank Scholz,
SVP, Global Operations -
George A. Kegler,
EVP & CFO, Interim -
Karen Patruno Sheehy,
Sr. VP & Chief Compliance Off. -
James E Deerfield Mgmt L.P....,
-
Don M Bailey,
Director -
Sandra L Hatten,
Sr. Vice President Quality -
Terrance L Carlson,
Interim General Counsel -
& Co. Inc. Paulson,
10% owner -
Holding Ltd Enceladus,
-
Thomas E Berry,
See Remarks -
Peter G Edwards,
See Remarks -
Stefano R Carchedi,
See Remarks -
Stephen Merrick,
See Remarks -
Nancy Lurker,
Director -
Mario D. Saltarelli,
Sr. VP & Chief Science Ofcr. -
Kathy A Schaefer,
Sr. VP Fin & Corp. Controller -
Peter C Richardson,
EVP & Chief Scientific Officer -
Daniel Arthur Celentano,
Director -
Woodrow A Jr Myers,
Director -
Paul Bisaro,
Director -
James R Sulat,
Director -
Susan Michele Silbermann,
Director -
Karen Ling,
Director -
Neal P Goldman,
Director -
Riad Hussein El Dada,
Director